Bacillus Calmette-Guerin (BCG) Vaccine Market

By Type;

Immune BCG and Therapy BCG

By Route Of Administration;

Intradermal and Percutaneous

By Application;

Tuberculosis Prevention and Bladder Cancer Treatmen

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn130207172 Published Date: August, 2025

BCG Vaccine Market Overview

BCG Vaccine Market (USD Million)

BCG Vaccine Market was valued at USD 5,235.65 million in the year 2024. The size of this market is expected to increase to USD 7,245.17 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.8%.


Bacillus Calmette-Guerin (BCG) Vaccine Market

*Market size in USD million

CAGR 4.8 %


Study Period2025 - 2031
Base Year2024
CAGR (%)4.8 %
Market Size (2024)USD 5,235.65 Million
Market Size (2031)USD 7,245.17 Million
Market ConcentrationHigh
Report Pages328
5,235.65
2024
7,245.17
2031

Major Players

  • Merck
  • Sanofi Pasteur
  • Japan BCG Lab
  • China National Biotec
  • Serum Institute of India
  • Intervax
  • GSBPL
  • GreenSignal
  • Statens Serum Institute
  • Shanyao Group

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Bacillus Calmette-Guerin (BCG) Vaccine Market

Fragmented - Highly competitive market without dominant players


The BCG Vaccine Market continues to play a critical role in global disease prevention strategies. Known for its effectiveness against tuberculosis, it is now drawing attention for its broader therapeutic potential. Around 65% of newborns in risk-prone areas are immunized with BCG, emphasizing its wide-scale implementation. Its reliability and cross-protective capabilities support its persistent demand across immunization programs.

Broadening Applications in Medical Practice
Growing use of the BCG vaccine in therapeutic applications, such as bladder cancer treatment, is reshaping the market landscape. Clinical research activity around these uses has surged by 28%, highlighting expanding clinical acceptance. As researchers explore its immunomodulatory effects, this has opened new revenue avenues for pharmaceutical stakeholders.

Advances in Production and Supply Dynamics
The vaccine’s manufacturing base is evolving, with about 48% of production units integrating updated technology protocols. These innovations enhance product stability and reduce batch variability. Strengthened partnerships between biotech companies and health institutes are ensuring more streamlined production and supply reliability.

Future Growth and Strategic Investments
The BCG vaccine market is gaining traction, driven by expanded research and revised immunization strategies. Investment in live vaccine technologies has grown by 33%, indicating a strategic focus on next-generation platforms. This trend is reinforcing the vaccine’s role in public health systems and shaping future market dynamics.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Route Of Administration
    3. Market Snapshot, By Application
    4. Market Snapshot, By Region
  4. BCG Vaccine Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising TB prevalence globally
        2. Emphasis on childhood immunization
        3. Government TB control initiatives
        4. Increased awareness about TB prevention
        5. High demand in high-risk populations
      2. Restraints
        1. Limited healthcare access
        2. Vaccine supply chain challenges
        3. Vaccine hesitancy and misinformation
        4. Regulatory hurdles
        5. Vaccine shortages
      3. Opportunities
        1. Innovative vaccine delivery methods
        2. Integration into existing healthcare services
        3. Healthcare worker training
        4. School-based vaccination programs
        5. Digital health solutions for tracking
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. BCG Vaccine Market, By Type, 2021 - 2031 (USD Million)
      1. Immune BCG
      2. Therapy BCG
    2. BCG Vaccine Market, By Route Of Administration, 2021 - 2031 (USD Million)

      1. Intradermal

      2. Percutaneous

    3. BCG Vaccine Market, By Application, 2021 - 2031 (USD Million)

      1. Tuberculosis Prevention

      2. Bladder Cancer Treatmen

    4. BCG Vaccine Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Merck
      2. Sanofi Pasteur
      3. Japan BCG Lab
      4. China National Biotec
      5. Serum Institute of India
      6. Intervax
      7. GSBPL
      8. GreenSignal
      9. Statens Serum Institute
      10. Shanyao Group
  7. Analyst Views
  8. Future Outlook of the Market